Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2000-11-21
pubmed:abstractText
The Fas-Fas ligand (FasL) interaction is important for maintaining lymphocyte homeostasis by signaling for activation-induced cell death. Mice homozygous for the lpr or gld mutations do not express functional Fas or FasL, respectively, and spontaneously develop progressive autoimmune symptoms. Recent studies implicated expression of FasL on immunologically privileged tissues in protection from immune-mediated damage. Conversely, tissue expression of Fas may facilitate damage. We evaluated the susceptibility of lpr and gld mice to induction of experimental autoimmune uveitis (EAU), a T cell-mediated autoimmune disease induced with retinal Ags, which targets the neural retina. gld as well as lpr mice immunized with a retinal Ag developed disease of lower incidence and severity than wild-type controls. Delayed hypersensitivity responses were not significantly different among immunized gld, lpr, or wild-type mice, although in vitro Ag-specific lymphocyte responses of the mutant mice were lower. To evaluate whether the diminished ability of gld and lpr mice to develop EAU was due to a defect at the level of the tissue or the immune system, radiation bone marrow chimeras constructed between wild-type and mutant mice were immunized to induce EAU. Mutant recipients of wild-type bone marrow, but not wild-type recipients of mutant bone marrow, developed normal disease scores. These results indicate that normal expression of Fas and of FasL on cells of the immune system is important for EAU expression. Unexpectedly, neither lack of Fas nor lack of FasL on the ocular tissues affected expression of EAU.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0022-1767
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
165
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5480-6
pubmed:dateRevised
2007-7-27
pubmed:meshHeading
pubmed-meshheading:11067900-Animals, pubmed-meshheading:11067900-Antigens, CD95, pubmed-meshheading:11067900-Autoimmune Diseases, pubmed-meshheading:11067900-Bone Marrow Transplantation, pubmed-meshheading:11067900-Cattle, pubmed-meshheading:11067900-Disease Susceptibility, pubmed-meshheading:11067900-Down-Regulation, pubmed-meshheading:11067900-Eye Proteins, pubmed-meshheading:11067900-Fas Ligand Protein, pubmed-meshheading:11067900-Genetic Predisposition to Disease, pubmed-meshheading:11067900-Immune System, pubmed-meshheading:11067900-Injections, Subcutaneous, pubmed-meshheading:11067900-Ligands, pubmed-meshheading:11067900-Membrane Glycoproteins, pubmed-meshheading:11067900-Mice, pubmed-meshheading:11067900-Mice, Congenic, pubmed-meshheading:11067900-Mice, Inbred C57BL, pubmed-meshheading:11067900-Mice, Inbred MRL lpr, pubmed-meshheading:11067900-Mice, Mutant Strains, pubmed-meshheading:11067900-Organ Specificity, pubmed-meshheading:11067900-Radiation Chimera, pubmed-meshheading:11067900-Retinitis, pubmed-meshheading:11067900-Retinol-Binding Proteins, pubmed-meshheading:11067900-Uveitis
pubmed:year
2000
pubmed:articleTitle
Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis.
pubmed:affiliation
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
pubmed:publicationType
Journal Article